AIM insider trading
HealthcareAIM ImmunoTech Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Company website: aimimmuno.com
AIM insider activity at a glance
FilingIQ has scored 122 insider transactions for AIM since Oct 17, 2018. The most recent filing in our index is dated Mar 12, 2026.
Across the full history, 39 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AIM insider trades is 68.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AIM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AIM?
- FilingIQ tracks 122 Form 4 insider transactions for AIM (AIM ImmunoTech Inc.), covering filings from Oct 17, 2018 onwards. 8 of those were filed in the last 90 days.
- Are AIM insiders net buyers or net sellers?
- Across the full Form 4 history for AIM, 39 transactions (32%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AIM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is AIM in?
- AIM ImmunoTech Inc. (AIM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.94M.
Methodology & sources
Every AIM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.